胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识

Consensus of Chinese experts on individualized medication management of imatinib for gastrointestinal stromal tumors

目的 为指导胃肠间质瘤(GIST)靶向药物伊马替尼的个体化用药管理,提高患者生存率、改善患者生活质量提供参考。方法 采用名义群体法,由多学科(临床、药学、循证)专家组成编写组,经共同讨论确定《胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识》编写大纲。编写组专家针对大纲涉及内容进行系统检索、分析、归纳,并根据我国现状、临床需求和研究证据制定相关共识。由临床实践经验丰富的多学科专家组成外审组。采用德尔菲法问卷方式,开放收集专家的外审意见,并对意见进行整理、归纳、分析、反馈、修订,最终形成共识。结果与结论 本共识内容包括伊马替尼针对GIST的新辅助治疗、手术切除后具有明显复发风险的成人患者的辅助治疗、复发转移性或不可切除患者的药物治疗的临床应用,药学监测及其长期用药管理。本共识的发布为我国医疗机构在GIST患者个体化用药管理方面提供了规范化的流程与方法,对提高伊马替尼的临床疗效、保障用药安全具有重要意义。

OBJECTIVE To provide reference for guiding the individualized drug therapy management of imatinib for gastrointestinal stromal tumor(GIST),with the goal of enhancing patient survival rates and improving their quality of life.METHODS Using a nominal group technique,a multidisciplinary(clinical,pharmaceutical and evidence-based)expert panel was formed to create the Consensus of Chinese Experts on Individualized Medication Management of Imatinib for Gastrointestinal Stromal Tumors outline through joint discussions.The expert panel conducted systematic retrieval,analysis,and summarization of the outline’s content,and reached relevant consensus based on China’s current situation,clinical needs,and research evidence.An external expert panel was also formed,comprising experienced multidisciplinary experts in clinical practice.Delphi method questionnaire was employed to openly collect the external experts’opinions,which were then organized,summarized,analyzed,provided with feedback,revised,and finally formed into a consensus.RESULTS&CONCLUSIONS The drafting of this consensus included the clinical application of imatinib in neoadjuvant therapy for GIST patients,adjuvant therapy for adult patients with significant risk of recurrence after surgical resection,and drug therapy for patients with recurrent,metastatic,or unresectable tumors;pharmaceutical monitoring and long-term medication management.This consensus provides standardized processes and methods for medical institutions in individualized drug therapy management for GIST patients and holds significant importance in improving the clinical efficacy of imatinib and ensuring drug safety.